Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients
Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients
复制标题
DOI：
10.1016/j.radonc.2020.07.014
复制
发表时间：
2020-10-01
影响因子：
5.7
通讯作者：
Kishan, Amar U.
中科院分区：
文献类型：
--
作者：
Levin-Epstein, Rebecca;Cook, Ryan R.;Kishan, Amar U.
背景与目的：立体定向体部放疗（SBRT）、低剂量率近距离放疗（LDR - BT）和高剂量率近距离放疗（HDR - BT）是前列腺癌（PCa）的消融性放疗选择。这些治疗方法在剂量给予方面差异很大，这可能会影响治疗后的前列腺特异性抗原（PSA）模式和生化控制。我们比较了SBRT、HDR - BT和LDR - BT之间的PSA动力学，并评估了它们与无生化复发生存率（BCRFS）的关系。
方法与材料：对1990年至2017年在10个机构接受治疗的3502名前列腺癌男性患者的回顾性PSA数据进行了分析，这些患者包括低风险（n = 2223；63.5%）、有利中风险（n = 869；24.8%）和不利中风险（n = 410；11.7%），分别接受了SBRT（n = 1716；49.0%）、HDR - BT（n = 512；14.6%）或LDR - BT（n = 1274；36.4%）治疗，且未预先进行雄激素剥夺治疗。我们比较了最低PSA（nPSA）、达到nPSA的时间、nPSA的实现情况……
Background and purpose: Stereotactic body radiation therapy (SBRT), low dose rate brachytherapy (LDR-BT) and high dose rate brachytherapy (HDR-BT) are ablative-intent radiotherapy options for prostate cancer (PCa). These vary considerably in dose delivery, which may impact post-treatment prostate-specific antigen (PSA) patterns and biochemical control. We compared PSA kinetics between SBRT, HDR-BT, and LDR-BT, and assessed their relationships to biochemical recurrence-free survival (BCRFS).Methods and materials: Retrospective PSA data were analyzed for 3502 men with low-risk (n = 2223; 63.5%), favorable intermediate-risk (n = 869; 24.8%), and unfavorable intermediate-risk (n = 410; 11.7%) PCa treated with SBRT (n = 1716; 49.0%), HDR-BT (n = 512; 14.6%), or LDR-BT (n = 1274; 36.4%) without upfront androgen deprivation therapy at 10 institutions from 1990 to 2017. We compared nadir PSA (nPSA), time to nPSA, achievement of nPSA